SQZ Biotechnologies Company (SQZ)
$0.435
Rating:
Recommendation:
-
| Symbol | SQZ |
|---|---|
| Price | $0.435 |
| Beta | 2.707 |
| Volume Avg. | 0.55M |
| Market Cap | 12.829M |
| Shares () | - |
| 52 Week Range | 0.25-3.56 |
| 1y Target Est | - |
| DCF Unlevered | SQZ DCF -> | |
|---|---|---|
| DCF Levered | SQZ LDCF -> | |
| ROE | -48.47% | Strong Sell |
| ROA | -42.08% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 61.01% | Buy |
| P/E | -0.20 | Neutral |
| P/B | 0.32 | Neutral |
Latest SQZ news
About
Download (Excel)SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.